Progyny Inc. [PGNY] stock is trading at $37.08, up 5.31%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PGNY shares have gain 10.85% over the last week, with a monthly amount glided 21.22%, and seem to be holding up well over a long-time horizon.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
On 9, January 2023, Progyny to Discuss its Strong 2022 Financial Performance at Upcoming Investor Conference. In a post published today on Yahoo Finance, Anticipates Results to be at the High-End of its Previously Provided Financial GuidanceAnticipates Reporting Record Fourth Quarter Operating Cash Flow of Approximately $50 Million.
From an analyst’s perspective:
Progyny Inc. [NASDAQ: PGNY] stock has seen the most recent analyst activity on January 05, 2023, when SVB Leerink downgraded its rating to a Mkt Perform but kept the price target unchanged to $34 for it. Previously, KeyBanc Capital Markets started tracking the stock with Overweight rating on September 16, 2022, and set its price target to $55. On September 07, 2022, Truist initiated with a Buy rating and assigned a price target of $56 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $60 on December 02, 2021. Citigroup downgraded its rating to a Neutral and raised its price target to $64 on November 22, 2021. Berenberg started tracking with a Buy rating for this stock on September 30, 2021, and assigned it a price target of $81. In a note dated August 12, 2021, Barclays initiated an Overweight rating and iterated a target price of $64 on this stock.
Progyny Inc. [PGNY] stock has fluctuated between $25.67 and $53.10 over the past year. Currently, Wall Street analysts expect the stock to reach $47.17 within the next 12 months. Progyny Inc. [NASDAQ: PGNY] shares were valued at $37.08 at the most recent close of the market. An investor can expect a potential return of 27.21% based on the average PGNY price forecast.
Analyzing the PGNY fundamentals
Progyny Inc. [NASDAQ:PGNY] reported sales of 205.37 billion for the most recent quarter, which represents a growth of 67.90%. Gross Margin for this corporation currently stands at +22.40% with Operating Margin at +6.46%, Pretax Margin comes in at +6.48%, and Net Margin reading is +13.14%.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 36.00 points at the first support level, and at 34.93 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.64, and for the 2nd resistance point, it is at 38.21.
Progyny Inc. [PGNY] reported earnings per share of $0.09 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.04/share, meaning a difference of $0.05 and a surprise factor of 125.00%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were $0.05 per share as compared to estimates of $0.01 per share, a difference of $0.04 representing a surprise of 400.00%.
Ratios To Look Out For
For context, Progyny Inc.’s Current Ratio is 2.60. As well, the Quick Ratio is 2.62, while the Cash Ratio is 1.21. Considering the valuation of this stock, the price to sales ratio is 10.09, the price to book ratio is 18.09 and the P/E (TTM) ratio is 88.29.
Transactions by insiders
Insider trading has also been a hot topic recently, with 7 insiders purchasing 149,666 shares and 44 selling 966,999 shares in the past 3 months. Recent insider trading involved Payson Norman, Director, that happened on Nov 23 when 200.0 shares were sold. Executive Chairman, Schlanger David J completed a deal on Feb 01 to sell 100000.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER Anevski Peter sold 32000.0 shares on Feb 01.